For patients who have watched the federal government wrestle with peptides like BPC-157 for years, something significant just changed. HHS has laid out an interim policy that could allow certain 503A pharmacies and physicians to compound six peptides without facing enforcement action simply because those substances have not yet completed the formal proc…
HHS Opens an Interim Path for BPC-157 and Five Other Peptides
The agency is not approving these peptides or permanently adding them to the 503A Bulks List. It is creating a temporary enforcement bridge while FDA finishes that process.
New to On The Pen? Start with The Weekly Dose podcast for the weekly breakdown.
